{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:59:11Z","timestamp":1792241951254,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ejphar.2019.05.022","type":"journal-article","created":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T10:58:52Z","timestamp":1557572332000},"page":"172393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR\/Nrf2 signaling in db\/db mice"],"prefix":"10.1016","volume":"858","author":[{"given":"Hongkui","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoli","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2019.05.022_bib1","doi-asserted-by":"crossref","unstructured":"2014. Diagnosis and classification of diabetes mellitus. Diabetes Care 37 Suppl. 1, S81-S90.","DOI":"10.2337\/dc14-S081"},{"key":"10.1016\/j.ejphar.2019.05.022_bib2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1023\/B:MCBI.0000028755.86521.11","article-title":"Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review","volume":"261","author":"Adeghate","year":"2004","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2019.05.022_bib3","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1161\/CIRCULATIONAHA.106.679597","article-title":"Diabetic cardiomyopathy revisited","volume":"115","author":"Boudina","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2019.05.022_bib4","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jacc.2006.07.022","article-title":"Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy","volume":"48","author":"Cai","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2019.05.022_bib5","first-page":"749307","article-title":"Effects of phenolic compounds of fermented Thai indigenous plants on oxidative stress in streptozotocin-induced diabetic rats. Evidence-based Complementary and Alternative Medicine","volume":"vol. 2011","author":"Chaiyasut","year":"2011","journal-title":"eCAM"},{"key":"10.1016\/j.ejphar.2019.05.022_bib6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2174\/138955711796355258","article-title":"Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA","volume":"11","author":"Fiorucci","year":"2011","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.05.022_bib7","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.292.20.2495","article-title":"Trends in cardiovascular complications of diabetes","volume":"292","author":"Fox","year":"2004","journal-title":"Jama"},{"key":"10.1016\/j.ejphar.2019.05.022_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9506925","article-title":"Cardiovascular protective effects of salvianic acid a on db\/db mice with elevated homocysteine level","author":"Gao","year":"2017","journal-title":"Oxidative Med. Cell Longev."},{"key":"10.1016\/j.ejphar.2019.05.022_bib9","doi-asserted-by":"crossref","first-page":"H1728","DOI":"10.1152\/ajpheart.01328.2005","article-title":"Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine","volume":"292","author":"Guo","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2019.05.022_bib10","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.yjmcc.2006.12.018","article-title":"Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy","volume":"42","author":"Hamblin","year":"2007","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejphar.2019.05.022_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/181643","article-title":"Molecular events linking oxidative stress and inflammation to insulin resistance and beta-cell dysfunction","volume":"2015","author":"Keane","year":"2015","journal-title":"Oxidative Med. Cell Longev."},{"key":"10.1016\/j.ejphar.2019.05.022_bib12","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1042\/BST0360930","article-title":"The sensitivity of pancreatic beta-cells to mitochondrial injuries triggered by lipotoxicity and oxidative stress","volume":"36","author":"Li","year":"2008","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejphar.2019.05.022_bib13","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/iub.1409","article-title":"Curcumin attenuates ethanol-induced hepatic steatosis through modulating Nrf2\/FXR signaling in hepatocytes","volume":"67","author":"Lu","year":"2015","journal-title":"IUBMB Life"},{"key":"10.1016\/j.ejphar.2019.05.022_bib14","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.3748\/wjg.v22.i41.9039","article-title":"Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease","volume":"22","author":"Makri","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2019.05.022_bib15","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.4049\/jimmunol.0901347","article-title":"The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis","volume":"183","author":"Mencarelli","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2019.05.022_bib16","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2019.05.022_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/506948","article-title":"Oxidative stress and inflammation in obesity, diabetes, hypertension, and related cardiometabolic complications","author":"Ndisang","year":"2014","journal-title":"Oxidative Med. Cell Longev."},{"key":"10.1016\/j.ejphar.2019.05.022_bib18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejphar.2019.05.022_bib19","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.05.022_bib20","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12681","article-title":"Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers","volume":"18","author":"Pencek","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2019.05.022_bib21","doi-asserted-by":"crossref","first-page":"21525","DOI":"10.3390\/ijms141121525","article-title":"Oxidative stress in diabetes: implications for vascular and other complications","volume":"14","author":"Pitocco","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2019.05.022_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10741-017-9663-y","article-title":"Hyperglycemia-induced cardiac contractile dysfunction in the diabetic heart","volume":"23","author":"Singh","year":"2018","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ejphar.2019.05.022_bib23","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/hep.27999","article-title":"Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis","volume":"62","author":"Singh","year":"2015","journal-title":"Hepatol. (Baltimore, Md)"},{"key":"10.1016\/j.ejphar.2019.05.022_bib24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jsbmb.2016.07.004","article-title":"Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension","volume":"165","author":"Vignozzi","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejphar.2019.05.022_bib25","doi-asserted-by":"crossref","first-page":"943","DOI":"10.4239\/wjd.v6.i7.943","article-title":"Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy","volume":"6","author":"Waddingham","year":"2015","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.ejphar.2019.05.022_bib26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1681\/ASN.2017020222","article-title":"FXR\/TGR5 dual agonist prevents progression of nephropathy in diabetes and obesity","volume":"29","author":"Wang","year":"2018","journal-title":"J. Am. Soc. Nephrol. : JASN (J. Am. Soc. Nephrol.)"},{"issue":"12","key":"10.1016\/j.ejphar.2019.05.022_bib27","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/s41401-018-0110-y","article-title":"18beta-Glycyrrhetinic acid protects against alpha-naphthylisothiocyanate-induced cholestasis through activation of the Sirt1\/FXR signaling pathway","volume":"39","author":"Wu","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2019.05.022_bib28","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.biopha.2018.05.135","article-title":"Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice","volume":"105","author":"Yan","year":"2018","journal-title":"Biomed. Pharmacother. Biomed. pharmacotherapie"},{"key":"10.1016\/j.ejphar.2019.05.022_bib29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bbrc.2015.09.067","article-title":"Farnesoid-X-receptor expression in monocrotaline-induced pulmonary arterial hypertension and right heart failure","volume":"467","author":"Ye","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2019.05.022_bib30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejphar.2018.09.009","article-title":"Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury","volume":"838","author":"Zhu","year":"2018","journal-title":"Eur. J. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919303267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919303267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:18:46Z","timestamp":1564359526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299919303267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":30,"alternative-id":["S0014299919303267"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.05.022","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR\/Nrf2 signaling in db\/db mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"172393"}}